Cargando…

Clinical significance of side population in ovarian cancer cells

Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosonuma, Shinji, Kobayashi, Yoichi, Kojo, Satoshi, Wada, Haruka, Seino, Ken-ichiro, Kiguchi, Kazushige, Ishizuka, Bunpei
Formato: Texto
Lenguaje:English
Publicado: Springer Japan 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051070/
https://www.ncbi.nlm.nih.gov/pubmed/21547690
http://dx.doi.org/10.1007/s13577-010-0002-z
_version_ 1782199433686941696
author Hosonuma, Shinji
Kobayashi, Yoichi
Kojo, Satoshi
Wada, Haruka
Seino, Ken-ichiro
Kiguchi, Kazushige
Ishizuka, Bunpei
author_facet Hosonuma, Shinji
Kobayashi, Yoichi
Kojo, Satoshi
Wada, Haruka
Seino, Ken-ichiro
Kiguchi, Kazushige
Ishizuka, Bunpei
author_sort Hosonuma, Shinji
collection PubMed
description Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP−), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP− (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer.
format Text
id pubmed-3051070
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-30510702011-04-05 Clinical significance of side population in ovarian cancer cells Hosonuma, Shinji Kobayashi, Yoichi Kojo, Satoshi Wada, Haruka Seino, Ken-ichiro Kiguchi, Kazushige Ishizuka, Bunpei Hum Cell Research Article Recently, accumulating evidence has suggested that tumors, including ovarian cancer, are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. The emergence of drug resistance is one of the most difficult problems in the treatment of ovarian cancer, which has been explained recently by the potential of CSCs to have superior resistance against anti-cancer drugs than conventional cancer cells. In this study, we expanded this line of study to examine whether this phenomenon is also observed in clinical specimens of ovarian cancer cells. In total we could analyze 28 samples out of 60 obtained from ovarian cancer patients. The clinical samples were subjected to testing of the expression of side population (SP) as a CSC marker, and according to the presence of SP (SP+) or absence of SP (SP−), clinicopathological significances were analyzed. Although there was no statistical significance, there were more SP+s in recurrent cases as well as in ascitic and peritoneal dissemination than in primary tumor of the ovary. There was no correlation between SP status and FIGO staging. In 19 cases of those who could be followed more than 6 months from initial therapy, there were 8 cases of recurrence or death from disease, and all of these were SP+. On the other hand, in 11 cases of disease-free survivors, 6 were SP+. There was a significant difference in prognosis between SP+ and SP− (p = 0.017). Although this study was limited, it revealed that SP could be contained more in recurrent or metastatic tumors than in primary tumors, and also that the presence of SP could be a risk factor of recurrence in ovarian cancer. Therefore, a novel therapeutic strategy targeting SP could improve the prognosis of ovarian cancer. Springer Japan 2011-01-07 2011 /pmc/articles/PMC3051070/ /pubmed/21547690 http://dx.doi.org/10.1007/s13577-010-0002-z Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Research Article
Hosonuma, Shinji
Kobayashi, Yoichi
Kojo, Satoshi
Wada, Haruka
Seino, Ken-ichiro
Kiguchi, Kazushige
Ishizuka, Bunpei
Clinical significance of side population in ovarian cancer cells
title Clinical significance of side population in ovarian cancer cells
title_full Clinical significance of side population in ovarian cancer cells
title_fullStr Clinical significance of side population in ovarian cancer cells
title_full_unstemmed Clinical significance of side population in ovarian cancer cells
title_short Clinical significance of side population in ovarian cancer cells
title_sort clinical significance of side population in ovarian cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051070/
https://www.ncbi.nlm.nih.gov/pubmed/21547690
http://dx.doi.org/10.1007/s13577-010-0002-z
work_keys_str_mv AT hosonumashinji clinicalsignificanceofsidepopulationinovariancancercells
AT kobayashiyoichi clinicalsignificanceofsidepopulationinovariancancercells
AT kojosatoshi clinicalsignificanceofsidepopulationinovariancancercells
AT wadaharuka clinicalsignificanceofsidepopulationinovariancancercells
AT seinokenichiro clinicalsignificanceofsidepopulationinovariancancercells
AT kiguchikazushige clinicalsignificanceofsidepopulationinovariancancercells
AT ishizukabunpei clinicalsignificanceofsidepopulationinovariancancercells